{
"id":"mk19_a_gi_s2",
"subspecialtyId":"gi",
"title":"Disorders of the Stomach and Duodenum",
"jsonContent":{
"type":"section",
"id":"mk19_a_gi_s2",
"title":{
"__html":"Disorders of the Stomach and Duodenum"
},
"titleNode":{
"type":"section-title",
"hlId":"c8fe01",
"children":[
"Disorders of the Stomach and Duodenum"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_1",
"title":{
"__html":"Dyspepsia"
},
"titleNode":{
"type":"section-title",
"hlId":"9b981c",
"children":[
"Dyspepsia"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_1_1",
"title":{
"__html":"Clinical Features"
},
"titleNode":{
"type":"section-title",
"hlId":"7962dd",
"children":[
"Clinical Features"
]
},
"children":[
{
"type":"p",
"hlId":"74b3cc",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Dyspepsia"
]
},
" is a term to describe epigastric pain. Associated symptoms can include early satiety, epigastric burning, nausea, and postprandial symptoms (e.g., pain, fullness, bloating, or belching). Heartburn may be present but is not a primary symptom; it may indicate coexisting gastroesophageal reflux. Recurrent vomiting should also raise concern for other conditions."
]
},
{
"type":"p",
"hlId":"d037ac",
"children":[
"The list of possible organic causes of dyspepsia is extensive ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t05",
"wrapId":"1",
"children":[
"Table 5"
]
}
]
},
")"
]
},
"; the most common are peptic ulcer disease and gastroesophageal reflux disease (20% of patients with erosive esophagitis report dyspepsia). If no structural, organic, or metabolic cause of dyspepsia symptoms is identified after evaluation, the term ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"functional dyspepsia"
]
},
" applies."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_gi_t05"
]
},
{
"type":"p",
"hlId":"c74f58",
"children":[
"Functional dyspepsia represents a heterogeneous group of gastrointestinal disorders predominated by one or more upper gastrointestinal symptoms. Diagnostic criteria for functional dyspepsia are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t06",
"wrapId":"2",
"children":[
"Table 6"
]
}
]
},
". Functional dyspepsia is further categorized into postprandial distress syndrome if the predominant symptoms are meal-induced ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t07",
"wrapId":"2",
"children":[
"Table 7"
]
}
]
},
")"
]
},
" or epigastric pain syndrome if the predominant symptoms are epigastric pain and/or burning ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t08",
"wrapId":"2",
"children":[
"Table 8"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_gi_t06",
"mk19_a_gi_t07",
"mk19_a_gi_t08"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_1_2",
"title":{
"__html":"Evaluation and Management"
},
"titleNode":{
"type":"section-title",
"hlId":"2f127d",
"children":[
"Evaluation and Management"
]
},
"children":[
{
"type":"p",
"hlId":"da83ab",
"children":[
"Testing for dyspepsia should be based on patient age, symptom severity, and risk for gastric cancer. Upper endoscopy is commonly performed to exclude upper gastrointestinal neoplasia; however, it is invasive and costly. Given the low incidence of malignancy and consideration for cost effectiveness in the evaluation of dyspepsia in younger adults, the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) have jointly recommended routine use of upper endoscopy only in patients age 60 years and older. The ACG/CAG guidelines recommend against routine use of upper endoscopy in patients younger than 60 years with dyspepsia, even in most patients with alarm features (weight loss, anemia, dysphagia, and vomiting) because these features poorly predict structural pathology, such as malignancy, peptic ulcer disease, or esophagitis. Endoscopy may be considered in younger patients at higher risk for malignancy, such as those with multiple or severe alarm features; those who have emigrated from regions with a high prevalence of malignancy (Asia, Russia, and South America); or those with a positive family history of gastric malignancy."
]
},
{
"type":"p",
"hlId":"1cc835",
"children":[
"For patients younger than 60 years with dyspepsia symptoms, the ACG/CAG guidelines recommend noninvasive testing for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
". Other testing, such as routine laboratory tests, screening for celiac disease, abdominal imaging, or gastric emptying, should be considered on an individual basis."
]
},
{
"type":"p",
"hlId":"fa2e8e",
"children":[
"Management of dyspepsia is directed at treating the cause. Patients who test positive for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" should receive eradication therapy. If ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" results are negative or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication does not relieve the dyspepsia, an empiric trial of a proton pump inhibitor (PPI) should be pursued. Patients diagnosed with functional dyspepsia can be treated with a variety of interventions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_gi_f08",
"wrapId":"3",
"children":[
"Figure 8"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_gi_f08"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"556c2c",
"hvc":true,
"children":[
"For patients with dyspepsia, routine upper endoscopy to exclude malignancy is reserved for patients age 60 years and older."
]
},
{
"type":"keypoint",
"hlId":"c88d56",
"hvc":true,
"children":[
"Upper endoscopy is not necessary in most patients with dyspepsia younger than 60 years, even in the presence of alarm symptoms."
]
},
{
"type":"keypoint",
"hlId":"56cc4a",
"hvc":true,
"children":[
"Patients younger than 60 years with dyspepsia symptoms should be tested and, if results are positive, treated for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_2",
"title":{
"__html":"Peptic Ulcer Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"9b8acc",
"children":[
"Peptic Ulcer Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_2_1",
"title":{
"__html":"Clinical Features, Diagnosis, and Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"5a685e",
"children":[
"Clinical Features, Diagnosis, and Complications"
]
},
"children":[
{
"type":"p",
"hlId":"99d54c",
"children":[
"The most frequently reported symptom of peptic ulcer disease (PUD) is epigastric pain, often described as worse during fasting and improved with eating or use of antacid or antisecretory therapy. Pain may be accompanied by early satiety, abdominal bloating, nausea, belching, or heartburn. Epigastric pain may be minimal or absent in elderly patients, immunosuppressed patients, and patients receiving long-term NSAID therapy."
]
},
{
"type":"p",
"hlId":"ee417b",
"children":[
"NSAIDs and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection are the most common causes of PUD, although idiopathic (NSAID-negative, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
"–negative) PUD is increasingly visible as a cause in the United States as the incidence of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection falls. The causes of idiopathic PUD remain unclear; however, cocaine, methamphetamine, bisphosphonates, selective serotonin reuptake inhibitors, smoking, excessive alcohol consumption, and stress have been implicated. Rare causes of PUD include gastrinoma (Zollinger-Ellison syndrome), systemic mastocytosis, α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency, COPD, chronic kidney disease, gastric cancer, gastric lymphoma, Crohn disease, eosinophilic gastroenteritis, herpes simplex virus, and cytomegalovirus (in immunocompromised patients)."
]
},
{
"type":"p",
"hlId":"4e6ecb",
"children":[
"PUD is most often diagnosed by upper endoscopy."
]
},
{
"type":"p",
"hlId":"1b5039",
"children":[
"Complications of PUD include bleeding, perforation, and obstruction. Overt bleeding presents with melena, hematemesis, and/or hematochezia, whereas obscure bleeding may present with iron deficiency anemia and/or stool that is positive for occult blood. Perforation typically presents with sudden, severe epigastric pain that can become more generalized along with peritoneal findings. Abdominal CT is the diagnostic study of choice for suspected perforating PUD (sensitivity, 98%). Symptoms associated with obstruction may include vomiting, early satiety, abdominal distention, and weight loss."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_2_2",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"bf4f8f",
"children":[
"Following confirmation of uncomplicated PUD, a once-daily PPI should be initiated and any agent causing PUD (such as an NSAID) should be discontinued. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection should be treated if identified and eradication confirmed after treatment. When results of tests for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" completed in the acute setting are negative, testing should be repeated after discharge."
]
},
{
"type":"p",
"hlId":"785342",
"children":[
"Upper endoscopy should be performed within 24 hours in patients with acute upper gastrointestinal bleeding. In patients with bleeding PUD, factors that increase risk for recurrent bleeding and/or death include tachycardia, hypotension, age older than 60 years, hemoglobin level less than 7 g/dL (70 g/L) (8 g/dL [80 g/L] in patients with cardiovascular disease), and comorbid illness. Interventions to address modifiable risks should be pursued before upper endoscopy. Nasogastric tube placement is not required before upper endoscopy. Use of PPIs before upper endoscopy may improve the endoscopic appearance of ulcer and reduce the need for endoscopic therapy."
]
},
{
"type":"p",
"hlId":"21aa56",
"children":[
"For bleeding PUD related to aspirin use for secondary cardiovascular prevention, aspirin should be restarted 1 to 7 days after initiation of PPI and cessation of bleeding. PPI therapy can be discontinued after confirmation of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication in patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori–"
]
},
"associated bleeding PUD. NSAIDs should be discontinued in patients with NSAID-induced bleeding PUD. If there is no effective alternative to NSAIDs, a selective cyclooxygenase-2 inhibitor plus a once-daily PPI should be used. Patients with idiopathic ulcers that have bled should receive once-daily PPI therapy indefinitely because of the substantial risk for rebleeding."
]
},
{
"type":"p",
"hlId":"b735cf",
"children":[
"Repeat upper endoscopy to verify ulcer resolution should be reserved for patients who have persistent symptoms after 8 to 12 weeks of therapy, have ulcers of unknown cause, or did not undergo gastric ulcer biopsy during initial upper endoscopy."
]
},
{
"type":"p",
"hlId":"282d55",
"children":[
"Perforated PUD is a surgical emergency, with a mortality rate of up to 30%; older age, comorbidity, and delayed surgery increase risk. Prompt identification, urgent surgical intervention, and proper preoperative and postoperative management of sepsis are essential. The cause of PUD (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" and/or NSAIDs) should be addressed, and postoperative upper endoscopy to rule out gastric cancer should be considered."
]
},
{
"type":"p",
"hlId":"da49ea",
"children":[
"Patients with gastric outlet obstruction from inflammation or scarring at the pylorus or proximal duodenum should have biopsy at the time of diagnosis to exclude malignancy. For mild symptoms, PPI therapy, treatment of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection (if identified), and/or cessation of NSAIDs may be effective. For severe or persistent symptoms, endoscopic dilation should be pursued, with surgery reserved for persistent obstruction following repeated attempts at endoscopic dilation."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"52e777",
"children":[
"NSAIDs and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection are the most common causes of peptic ulcer disease."
]
},
{
"type":"keypoint",
"hlId":"6a3bc6",
"children":[
"For bleeding peptic ulcer disease related to aspirin use for secondary cardiovascular prevention, aspirin should be restarted 1 to 7 days after initiation of PPI and cessation of bleeding."
]
},
{
"type":"keypoint",
"hlId":"1e1d8b",
"children":[
"NSAIDs should be discontinued in patients with NSAID-induced bleeding peptic ulcer disease; if there is no effective alternative to NSAIDs, a selective cyclooxygenase-2 inhibitor plus a once-daily PPI should be used."
]
},
{
"type":"keypoint",
"hlId":"5d60fc",
"children":[
"Patients with idiopathic ulcers that have bled should receive once-daily PPI therapy indefinitely because of the substantial risk for rebleeding."
]
},
{
"type":"keypoint",
"hlId":"72b9e1",
"hvc":true,
"children":[
"Repeat upper endoscopy to verify ulcer resolution is reserved for patients who have persistent symptoms after 8 to 12 weeks of therapy, have ulcers of unknown cause, or did not undergo gastric ulcer biopsy during the initial upper endoscopy."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_3",
"title":{
"__html":"<i>Helicobacter pylori</i> Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"bbf478",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" Infection"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_3_1",
"title":{
"__html":"Indications for Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"f2da68",
"children":[
"Indications for Testing"
]
},
"children":[
{
"type":"p",
"hlId":"2bcac0",
"children":[
"Indications for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" testing include active PUD, history of PUD without documented cure of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection, gastric mucosa–associated lymphoid tissue lymphoma, or history of endoscopic resection of early gastric cancer. Other conditions in which ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" testing should be considered include dyspepsia, before long-term low-dose aspirin or NSAID use, unexplained iron deficiency anemia, and idiopathic thrombocytopenic purpura in adults. Routine testing for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" is not indicated in patients with typical gastroesophageal reflux disease symptoms, lymphocytic gastritis, hyperplastic gastric polyps, or hyperemesis gravidarum or in asymptomatic individuals with a family history of gastric cancer."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_3_2",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"00c22e",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection can be diagnosed with gastric biopsies during upper endoscopy or noninvasively by ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath, stool antigen, or serologic testing. The ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath test and the monoclonal stool antigen test are preferred noninvasive tests because sensitivity and specificity both exceed 95% for active infection. Serologic testing for IgG antibodies against ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" is the cheapest and most convenient method; however, it cannot distinguish between active and previous infection. Although the negative predictive value of serologic testing is reasonably high, a positive serologic result in a population with low prevalence of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection, such as in the United States, may require confirmation with the ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath test, stool antigen test, or gastric biopsy. Serologic testing is most useful as an adjunct test in patients with bleeding PUD because of the decreased sensitivity of biopsy in acute bleeding. Conditions that lower ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" density, such as PPI use, recent antibiotic use, atrophic gastritis, intestinal metaplasia, or mucosa-associated lymphoid tissue lymphoma, can result in false-negative results on the noninvasive studies. Upper endoscopy that is done to evaluate dyspepsia should include gastric biopsy for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" testing."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_3_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"9edb04",
"children":[
"Any patient with a test result positive for active infection requires treatment with the goal of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication. The first course of treatment offers the best chance of eradication and should be carefully chosen. Several first-line treatments are available, with the choice based on resistance patterns of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
", previous antibiotic use by the patient, and antibiotic allergies ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t09",
"wrapId":"4",
"children":[
"Table 9"
]
}
]
},
")"
]
},
". In most cases, duration of therapy is 14 days. When treatment fails, second-line therapy should last a minimum of 14 days, ideally with antibiotics different from those used for initial treatment ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t10",
"wrapId":"4",
"children":[
"Table 10"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_gi_t09",
"mk19_a_gi_t10"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_3_4",
"title":{
"__html":"Eradication Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"9687ba",
"children":[
"Eradication Testing"
]
},
"children":[
{
"type":"p",
"hlId":"0e62f8",
"children":[
"No sooner than 4 weeks after completion of eradication therapy and cessation of PPI therapy (if possible), eradication of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" should be tested by using a ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath test, fecal antigen test, or gastric biopsy performed during upper endoscopy. Serologic testing is not used to confirm ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication because results can remain positive following ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1dd81c",
"children":[
"Gastric biopsies during upper endoscopy or noninvasive testing methods, including ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath and stool antigen tests, can confirm active ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection; negative serologic results can exclude infection, but a positive serologic result may require confirmation."
]
},
{
"type":"keypoint",
"hlId":"0fedea",
"children":[
"Treatment regimens for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" consist of a minimum of three agents, including two antimicrobial agents and one antisecretory agent; treatment duration is 14 days in most cases."
]
},
{
"type":"keypoint",
"hlId":"a789da",
"children":[
"Eradication of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" is tested with a ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-urea breath test, fecal antigen test, or gastric biopsy performed during upper endoscopy no sooner than 4 weeks after completion of eradication therapy and cessation of PPI therapy (if possible)."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_4",
"title":{
"__html":"Miscellaneous Gastropathy"
},
"titleNode":{
"type":"section-title",
"hlId":"432c42",
"children":[
"Miscellaneous Gastropathy"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_4_1",
"title":{
"__html":"Erosive Gastropathy"
},
"titleNode":{
"type":"section-title",
"hlId":"8cb76a",
"children":[
"Erosive Gastropathy"
]
},
"children":[
{
"type":"p",
"hlId":"343c03",
"children":[
"Erosive gastropathy can result from exposure to medications and toxins, including NSAIDs, iron, and alcohol. Ischemia and portal hypertension are additional causes. Although erosive gastropathy may result in gastrointestinal bleeding, it rarely causes clinically significant bleeding."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_4_2",
"title":{
"__html":"Atrophic Gastritis"
},
"titleNode":{
"type":"section-title",
"hlId":"1be310",
"children":[
"Atrophic Gastritis"
]
},
"children":[
{
"type":"p",
"hlId":"cf88ab",
"children":[
"Chronic atrophic gastritis can present as environmental metaplastic atrophic gastritis, also called ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"multifocal atrophic gastritis"
]
},
", or as autoimmune atrophic gastritis. Environmental metaplastic atrophic gastritis is the result of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection and typically lessens after ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" eradication. Autoimmune atrophic gastritis is caused by formation of autoantibody to parietal cell antigens and is commonly associated with pernicious anemia. The achlorhydria from chronic atrophic gastritis can lead to iron deficiency, small intestinal bacterial overgrowth, and enteric infections. The hypergastrinemia associated with autoimmune atrophic gastritis can promote development of gastric neuroendocrine tumors. Goals of therapy for autoimmune atrophic gastritis include prevention of pernicious anemia and iron deficiency with vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" supplementation and iron replacement along with surveillance for gastric neoplasm. See ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s4_2_5",
"children":[
"MKSAP 19 Hematology"
]
},
" for further discussion of pernicious anemia in the setting of autoimmune gastritis. Screening upper endoscopy with gastric biopsy is recommended for patients with pernicious anemia. Otherwise, there are no universally accepted surveillance protocols for gastric neoplasm in chronic atrophic gastritis, and endoscopic surveillance should be considered on an individual basis. Annual endoscopy is generally not necessary."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_4_3",
"title":{
"__html":"Gastric Intestinal Metaplasia"
},
"titleNode":{
"type":"section-title",
"hlId":"da8fdf",
"children":[
"Gastric Intestinal Metaplasia"
]
},
"children":[
{
"type":"p",
"hlId":"916d6e",
"children":[
"Gastric intestinal metaplasia is a preneoplastic gastropathy frequently arising from chronic inflammation associated with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection. As such, patients with gastric intestinal metaplasia should be tested for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" and then treated if the infection is identified. Other causes of chronic inflammation, including other gastric infections, chemical agents, and autoimmune disease, may also promote progression to gastric intestinal metaplasia. No conclusive evidence shows that long-term PPI use promotes development of intestinal metaplasia. Gastric intestinal metaplasia is believed to be an intermediary stage in the multistage progression from chronic atrophic gastritis to gastric adenocarcinoma. If metaplasia is secondary to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection, eradication therapy may decrease progression to gastric adenocarcinoma. Given the rarity of gastric adenocarcinoma in the United States, current guidelines recommend against the routine use of surveillance endoscopy in gastric intestinal metaplasia. The American Gastroenterological Society recommends that surveillance endoscopy be considered in patients at increased risk (such as those with complete or extensive gastric intestinal metaplasia on endoscopy; those with a family history of gastric cancer; certain racial/ethnic minority groups; or those who have emigrated from East Asia, Russia, or South America)."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_4_4",
"title":{
"__html":"Eosinophilic Gastritis"
},
"titleNode":{
"type":"section-title",
"hlId":"0e6d19",
"children":[
"Eosinophilic Gastritis"
]
},
"children":[
{
"type":"p",
"hlId":"15d741",
"children":[
"Eosinophilic gastritis is a rare gastropathy characterized by infiltration of eosinophils in the gastric mucosa. Secondary causes of eosinophilia should first be excluded, including parasitic and bacterial infections of the stomach, inflammatory bowel disease, hypereosinophilic syndrome, myeloproliferative disorders, polyarteritis nodosa, allergic vasculitis, scleroderma, drug injury, and drug hypersensitivity. The cause of primary eosinophilic gastritis is unknown but is believed to be an allergic process. Symptoms vary widely based on depth of eosinophilia and other gastrointestinal tract involvement. Treatment includes avoidance of food allergens, elemental diets, and/or glucocorticoids."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_4_5",
"title":{
"__html":"Lymphocytic Gastritis"
},
"titleNode":{
"type":"section-title",
"hlId":"f08242",
"children":[
"Lymphocytic Gastritis"
]
},
"children":[
{
"type":"p",
"hlId":"84616e",
"children":[
"Lymphocytic gastritis is a rare gastropathy typically presenting with nonspecific dyspeptic symptoms and a normal-appearing stomach on endoscopy. On occasion, the stomach may have thickened folds covered by small nodules and aphthous ulceration. Celiac disease is the most common cause of lymphocytic gastritis. Other causes include HIV infection, Crohn disease, common variable immunodeficiency, and, rarely, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" infection."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9b5f33",
"children":[
"Autoimmune atrophic gastritis is associated with pernicious anemia, iron deficiency, small intestinal bacterial overgrowth, and gastric carcinoid."
]
},
{
"type":"keypoint",
"hlId":"556eb2",
"children":[
"Management of autoimmune atrophic gastritis includes prevention of pernicious anemia and iron deficiency with vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" supplementation and iron replacement along with surveillance for gastric neoplasm."
]
},
{
"type":"keypoint",
"hlId":"ae0383",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" is associated with upper gastrointestinal conditions other than peptic ulcer disease, including environmental metaplastic atrophic gastritis, gastric intestinal metaplasia, and, rarely, lymphocytic gastritis."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_5",
"title":{
"__html":"Gastrointestinal Complications of NSAIDs"
},
"titleNode":{
"type":"section-title",
"hlId":"eedd3d",
"children":[
"Gastrointestinal Complications of NSAIDs"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_5_1",
"title":{
"__html":"Epidemiology and Risk Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"ba37ab",
"children":[
"Epidemiology and Risk Factors"
]
},
"children":[
{
"type":"p",
"hlId":"fc0f4f",
"children":[
"Upper gastrointestinal complications can occur with short- or long-term NSAID use and are dose dependent, with a linear increase in incidence over time. Nearly 1% to 2% of patients taking long-term NSAID therapy experience a clinically significant upper gastrointestinal event (bleeding ulcer, perforation, or obstruction) annually. The rate of upper gastrointestinal adverse events rises to 14% for elderly NSAID users. The greatest risk factor for NSAID-related upper gastrointestinal complication is a history of gastrointestinal bleeding. Risk factors are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t11",
"wrapId":"5",
"children":[
"Table 11"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_gi_t11"
]
},
{
"type":"p",
"hlId":"186bec",
"children":[
"Use of low-dose aspirin for cardioprophylaxis is associated with a twofold to fourfold increase in risk for upper gastrointestinal complications, including bleeding ulcer, perforation, and obstruction. Use of enteric-coated aspirin does not lower this risk, and an increase in aspirin dosage is associated with an increased risk for upper gastrointestinal complications. See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_4",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for discussion of indications for primary and secondary prevention of cardiovascular disease with aspirin."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_5_2",
"title":{
"__html":"Prevention of NSAID-Induced Injury"
},
"titleNode":{
"type":"section-title",
"hlId":"0b5c24",
"children":[
"Prevention of NSAID-Induced Injury"
]
},
"children":[
{
"type":"p",
"hlId":"fee8c7",
"children":[
"Prevention of NSAID-related upper gastrointestinal adverse events includes avoiding NSAIDs; addressing modifiable risk factors; coadministering gastroprotective agents, such as PPIs, misoprostol, or H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-blockers; or using a selective cyclooxygenase (COX)-2 inhibitor. PPIs are the preferred gastroprotective agent for the treatment and prophylaxis of NSAID-related (including aspirin-related) upper gastrointestinal complications and are superior to H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-blockers for preventing PUD and bleeding related to low-dose aspirin use. Misoprostol may be used instead of PPIs in patients intolerant of or unwilling to take PPIs. However, side effects of misoprostol, such as diarrhea, abdominal discomfort, and nausea, can be limiting, and the drug is contraindicated in pregnancy."
]
},
{
"type":"p",
"hlId":"719c61",
"children":[
"Selective COX-2 inhibitors are associated with decreased risk for gastrointestinal toxicity compared with NSAIDs, although the risk is still elevated. When coadministered with aspirin, however, a selective COX-2 inhibitor provides no advantage over an NSAID in preventing an upper gastrointestinal adverse event. Given the increased risk for PUD with concomitant use of an NSAID or selective COX-2 inhibitor with low-dose aspirin, at-risk individuals should receive gastroprotective therapy. Compared to an NSAID plus a PPI in patients at high risk, a selective COX-2 inhibitor plus a PPI offers a lower risk for perforation, obstruction, and bleeding as well as for NSAID and COX-2 withdrawal due to gastrointestinal adverse events."
]
},
{
"type":"p",
"hlId":"ef3395",
"children":[
"After an NSAID-induced bleeding peptic ulcer, the safest strategy is avoidance of future NSAID use. If an NSAID must be used, the combination of a selective COX-2 inhibitor plus a PPI provides the best gastrointestinal protection to prevent rebleeding."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"130b6e",
"children":[
"Upper gastrointestinal complications, such as bleeding, are common with use of NSAIDs (both short- and long-term) and low-dose aspirin."
]
},
{
"type":"keypoint",
"hlId":"ec0548",
"children":[
"Proton pump inhibitors are the preferred agent for preventing and treating NSAID-related (including aspirin-related) upper gastrointestinal complications."
]
},
{
"type":"keypoint",
"hlId":"078898",
"children":[
"In individuals with high risk for gastrointestinal complications, including those with previous NSAID-induced gastrointestinal bleeding, the combination of a selective cyclooxygenase-2 inhibitor plus a proton pump inhibitor provides the best gastrointestinal protection if avoidance of NSAIDs is not possible."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_6",
"title":{
"__html":"Gastroparesis"
},
"titleNode":{
"type":"section-title",
"hlId":"c876b0",
"children":[
"Gastroparesis"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_6_1",
"title":{
"__html":"Presentation"
},
"titleNode":{
"type":"section-title",
"hlId":"c7bc3f",
"children":[
"Presentation"
]
},
"children":[
{
"type":"p",
"hlId":"31ad47",
"children":[
"Gastroparesis is a heterogeneous clinical syndrome characterized by the presence of specific symptoms, absence of mechanical outlet obstruction, and objective evidence of delay in gastric emptying into the duodenum. The most common symptoms, in order of prevalence, are nausea (90%), vomiting (84%), upper abdominal pain (72%), and early satiety (60%). Other symptoms may include abdominal fullness and bloating. Symptoms may be chronic or persistent or may occur intermittently. More severe cases may involve weight loss and evidence of malnutrition and/or dehydration. A viral prodrome, such as gastroenteritis or respiratory infection before symptom onset, may suggest postviral gastroparesis, a condition that can resolve over time. Gastroparesis has a variety of causes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t12",
"wrapId":"6",
"children":[
"Table 12"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_gi_t12"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_6_2",
"title":{
"__html":"Diagnostic Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"640bda",
"children":[
"Diagnostic Testing"
]
},
"children":[
{
"type":"p",
"hlId":"9546b3",
"children":[
"The first study to evaluate suspected gastroparesis is upper endoscopy to exclude gastric outlet obstruction. Once a structural cause for symptoms has been excluded, an objective test to assess gastric emptying is performed: gastric scintigraphy, wireless motility capsule, or gastric emptying carbon breath test using ",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"13"
]
},
"C-labeled ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Spirulina platensis"
]
},
" ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_gi_t13",
"wrapId":"7",
"children":[
"Table 13"
]
}
]
},
")"
]
},
". Gastric scintigraphy is the most commonly used, but the optimal duration of this study is 4 hours. Narcotic and anticholinergic agents must be stopped at least 72 hours before a gastric emptying study. Once delayed emptying is objectively confirmed, additional testing may be required to determine the cause of the gastroparesis."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_gi_t13"
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_6_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"a3e49b",
"children":[
"Symptom severity does not correlate with severity of delayed gastric emptying, particularly with regard to abdominal bloating and epigastric pain. This suggests that gastroparesis is not simply a motility disorder but also a disorder of altered sensation. Initial management includes correcting dehydration and electrolyte abnormalities along with nutritional support if needed. Initial dietary intervention should consist of small, frequent meals that are low in fat and soluble fiber. Referral to a dietitian may be beneficial. In diabetic gastroparesis, poor glycemic control (blood glucose level >200 mg/dL [11.1 mmol/L]) can worsen symptoms as well as gastric emptying, and tight glycemic control is the most important element of treatment."
]
},
{
"type":"p",
"hlId":"1be633",
"children":[
"Pharmacologic therapy is used to improve gastric emptying and treat symptoms. Metoclopramide is the only prokinetic approved in the United States for treatment of gastroparesis. To minimize the significant risk for neurologic side effects (dystonia, parkinsonian movements, tardive dyskinesia), the lowest effective dose should be used. Therapy must be stopped immediately if neurologic side effects develop."
]
},
{
"type":"p",
"hlId":"784999",
"children":[
"Erythromycin improves gastric emptying, but use should be limited to treatment of flares or short-term use (2 to 3 weeks) because of risk for tachyphylaxis."
]
},
{
"type":"p",
"hlId":"9ea7b9",
"children":[
"Antiemetics and centrally acting modulators, including tricyclic antidepressants and mirtazapine, can also relieve symptoms but have no beneficial effect on gastric emptying."
]
},
{
"type":"p",
"hlId":"c7cc3a",
"children":[
"Interventional therapy, such as enteral feeding via jejunostomy, gastric stimulator placement, gastric peroral endoscopic myotomy, pyloroplasty, and subtotal or total gastrectomy, can be considered in patients who do not respond to dietary and pharmacologic therapy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"b7bac0",
"children":[
"After gastric outlet obstruction is excluded by upper endoscopy, patients suspected of gastroparesis should undergo an objective test of gastric emptying, typically gastric scintigraphy."
]
},
{
"type":"keypoint",
"hlId":"d1d553",
"children":[
"Initial management of gastroparesis includes correcting dehydration and electrolyte abnormalities; nutritional support; small, frequent meals that are low in fat and soluble fiber; and, in patients with diabetes mellitus, improved glycemic control."
]
},
{
"type":"keypoint",
"hlId":"2920e6",
"children":[
"Metoclopramide is a prokinetic drug that improves gastric emptying but is associated with dystonia, tardive dyskinesia, and parkinsonism."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_7",
"title":{
"__html":"Gastric Polyps and Subepithelial Lesions"
},
"titleNode":{
"type":"section-title",
"hlId":"173dd3",
"children":[
"Gastric Polyps and Subepithelial Lesions"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_7_1",
"title":{
"__html":"Gastric Polyps"
},
"titleNode":{
"type":"section-title",
"hlId":"ff642f",
"children":[
"Gastric Polyps"
]
},
"children":[
{
"type":"p",
"hlId":"727dd6",
"children":[
"Polyps in the stomach include fundic gland polyps, hyperplastic polyps, and adenomas. All gastric polyps should be biopsied to determine polyp histology. Fundic gland polyps and hyperplastic polyps account for 70% to 90% of stomach polyps. Fundic gland polyps have no potential for malignancy and are common with PPI use. Multiple fundic gland polyps are also found in patients with familial adenomatous polyposis."
]
},
{
"type":"p",
"hlId":"68668d",
"children":[
"Hyperplastic polyps of the stomach are thought to have malignant potential, with 5% to 19% harboring dysplasia or malignancy. Risk factors for malignant potential of hyperplastic polyps include size greater than 1 cm and pedunculated morphology. All hyperplastic polyps greater than 0.5 to 1.0 cm should be resected."
]
},
{
"type":"p",
"hlId":"a24557",
"children":[
"Adenomas in the stomach can be sporadic or associated with hereditary syndromes, including familial adenomatous polyposis and Lynch syndrome. Those in the stomach should be resected and endoscopic surveillance should be performed 1 year after resection and then every 3 to 5 years thereafter."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_7_2",
"title":{
"__html":"Gastric Subepithelial Lesions"
},
"titleNode":{
"type":"section-title",
"hlId":"ea10c0",
"children":[
"Gastric Subepithelial Lesions"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_7_2_1",
"title":{
"__html":"Gastrointestinal Stromal Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"994b92",
"children":[
"Gastrointestinal Stromal Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"2031c0",
"children":[
"Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the stomach. GISTs may present with symptoms, such as bleeding or abdominal pain, but are also found incidentally. Endoscopic ultrasonography is the best diagnostic modality for evaluation of a GIST. High-risk features on endoscopic ultrasonography include size greater than 2 cm, lobulated or irregular borders, invasion into adjacent structures, and heterogeneity. A GIST can be biopsied, but the high-risk endoscopic features are better predictors of malignant potential. Treatment consists of surgical or endoscopic excision if the GIST is symptomatic or high-risk features are present. For GISTs without high-risk features, yearly endoscopic surveillance is indicated. See ",
{
"type":"cross-reference",
"target":"mk19_a_on_s5_7",
"children":[
"MKSAP 19 Oncology"
]
},
" for staging and treatment of GISTs."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_7_2_2",
"title":{
"__html":"Gastrointestinal Neuroendocrine Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"974a2d",
"children":[
"Gastrointestinal Neuroendocrine Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"71ef6e",
"children":[
"Neuroendocrine tumors (NETs; formerly called carcinoid tumors) are well-differentiated lesions originating in the digestive tract, lungs, or, rarely, kidneys or ovaries. NETs can be encountered throughout the gastrointestinal tract, including the stomach. They may present symptomatically or may be found incidentally. These tumors are usually sporadic but can be seen in the setting of Zollinger-Ellison syndrome; atrophic gastritis; and rare syndromes, such as multiple endocrine neoplasia type 1 and neurofibromatosis type 1. NETs are classified by size, number, and anatomic distribution. Management of gastrointestinal NETs includes endoscopic surveillance for lesions smaller than 1 cm, especially when multiple lesions are present. Endoscopic or surgical excision is indicated for gastrointestinal NETs with high-risk features, such as solitary lesions not found in the setting of atrophic gastritis or Zollinger-Ellison syndrome. See ",
{
"type":"cross-reference",
"target":"mk19_a_on_s5_6",
"children":[
"MKSAP 19 Oncology"
]
},
" for treatment of gastrointestinal NETs."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e9cfdd",
"children":[
"Polyps in the stomach include fundic gland polyps, which have no malignant potential; polyps with malignant potential, including hyperplastic polyps, and adenomas should be resected."
]
},
{
"type":"keypoint",
"hlId":"fedf50",
"children":[
"Gastrointestinal stromal tumors should be evaluated with endoscopic ultrasonography and excised if symptoms or high-risk features are present."
]
},
{
"type":"keypoint",
"hlId":"6c129f",
"children":[
"Neuroendocrine tumors are usually sporadic but can be seen in the setting of Zollinger-Ellison syndrome; atrophic gastritis; and rare syndromes, such as multiple endocrine neoplasia type 1 and neurofibromatosis type 1."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_8",
"title":{
"__html":"Gastric Adenocarcinoma"
},
"titleNode":{
"type":"section-title",
"hlId":"47afb4",
"children":[
"Gastric Adenocarcinoma"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_gi_s2_8_1",
"title":{
"__html":"Epidemiology and Risk Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"ba37ab",
"children":[
"Epidemiology and Risk Factors"
]
},
"children":[
{
"type":"p",
"hlId":"d9ca47",
"children":[
"Stomach adenocarcinoma has an incidence of 6.6 in 100,000 persons and a mortality of 3.1 per 100,000 persons in the United States. Rates have steadily decreased since the 1990s. The two types of gastric cancer are intestinal-type, which is more common, and diffuse-type. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" is a recognized risk factor for both types and is the primary nongenetic risk factor for gastric cancer. Other risk factors primarily associated with intestinal-type gastric adenocarcinoma include male sex; ethnicity (incidence is highest in persons of Asian and Pacific Island descent); geography (the highest rates worldwide occur in Asia, Eastern Europe, and Central and South America); a diet high in smoked, salted, and pickled foods as well as nitrates and nitrites; smoking; and obesity. Additional risk factors include previous stomach surgery; chronic atrophic gastritis; and hereditary syndromes, such as hereditary diffuse gastric cancer (associated with the diffuse type), Lynch syndrome, and familial adenomatous polyposis. Gastric intestinal metaplasia and dysplasia are also risk factors for gastric adenocarcinoma."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_8_2",
"title":{
"__html":"Screening and Surveillance"
},
"titleNode":{
"type":"section-title",
"hlId":"a38736",
"children":[
"Screening and Surveillance"
]
},
"children":[
{
"type":"p",
"hlId":"6daee6",
"children":[
"There is no recommendation for population-based screening for gastric adenocarcinoma in countries with a low incidence of gastric cancer, such as the United States. Intestinal metaplasia with high-grade dysplasia should be resected because 25% of cases progress to adenocarcinoma. Screening and surveillance are indicated for patients with familial adenomatous polyposis and Lynch syndrome."
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_8_3",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"d7a7c0",
"children":[
"Symptoms of gastric adenocarcinoma may be vague. They include poor appetite, weight loss, abdominal pain, early satiety, nausea, and vomiting. Signs of gastric adenocarcinoma include iron deficiency anemia. Diagnosis is typically made by upper endoscopy with biopsy."
]
},
{
"type":"p",
"hlId":"4830dd",
"children":[
"For treatment of gastric cancer, see ",
{
"type":"cross-reference",
"target":"mk19_a_on_s5_4",
"children":[
"MKSAP 19 Oncology"
]
},
"."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"933b62",
"children":[
"The primary nongenetic risk factor for gastric cancer is ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection."
]
},
{
"type":"keypoint",
"hlId":"8241a5",
"hvc":true,
"children":[
"In countries with a low incidence of gastric cancer, such as the United States, screening for gastric cancer should be reserved for patients with genetic cancer syndromes."
]
},
{
"type":"keypoint",
"hlId":"7df0c0",
"children":[
"Upper endoscopy with biopsy is the diagnostic test of choice for gastric cancer."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_9",
"title":{
"__html":"Gastric Surgery Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"d045a9",
"children":[
"Gastric Surgery Complications"
]
},
"children":[
{
"type":"p",
"hlId":"6380b5",
"children":[
"For complications of bariatric surgery, see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s5_3_3_2",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
"."
]
},
{
"type":"p",
"hlId":"ecfc52",
"children":[
"Partial or complete gastric resections are performed for benign and malignant disease. The extent of resection, type of reconstruction, and nature of the disease affect postoperative morbidity and mortality. Partial resection allows preservation of some function of the stomach, but patients with malignancy require lifelong surveillance of the remaining stomach for recurrence. Patients who undergo partial gastrectomy for benign disease also have an increased risk for cancer in the gastric remnant 15 to 20 years after surgery, with reported frequency ranging from 0.8% to 8.9%."
]
},
{
"type":"p",
"hlId":"565068",
"children":[
"Dumping syndrome, which results from rapid gastric emptying after gastric surgery, can cause significant postprandial gastrointestinal and vasomotor symptoms. Clinical features of early dumping syndrome occur within 30 minutes of eating due to gastrointestinal hormone hypersecretion, autonomic dysregulation, and bowel distention. Symptoms include palpitations, flushing or pallor, diaphoresis, light-headedness, hypotension, and fatigue, followed by diarrhea, nausea, abdominal bloating, cramping, and borborygmus. Symptoms of late dumping syndrome occur 1 to 3 hours after meals because of reactive hypoglycemia and can include decreased concentration, faintness, and altered consciousness. In severe cases, protein-wasting malnutrition can occur."
]
},
{
"type":"p",
"hlId":"916b80",
"children":[
"Roughly 25% to 50% of all patients who have undergone gastric surgery experience some symptoms of dumping syndrome, but severe, persistent symptoms occur in only about 10%. Oral glucose challenge testing helps make the diagnosis, with a sensitivity of nearly 100% and a specificity of 94%."
]
},
{
"type":"p",
"hlId":"614c06",
"children":[
"First-line treatment for dumping syndrome is dietary, with smaller, more frequent meals and ingestion of liquids after meals. Decreasing carbohydrate intake, especially simple carbohydrates, and increasing protein and fiber intake may also alleviate symptoms."
]
},
{
"type":"p",
"hlId":"62aa11",
"children":[
"Acarbose, an α-glycosidase hydrolase inhibitor that interferes with digestion of polysaccharides to monosaccharides, can be used for late symptoms of dumping syndrome. Other pharmacologic therapies include anticholinergics to slow gastric emptying and antispasmodics. Severe cases of dumping rarely require octreotide. If a trial of subcutaneous injections is effective, monthly intramuscular injections of long-acting octreotide can be used."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2befd4",
"children":[
"Patients who undergo partial gastrectomy for malignancy require lifelong surveillance for cancer recurrence; patients who have undergone partial gastrectomy for benign disease also have an increased risk for gastric cancer."
]
},
{
"type":"keypoint",
"hlId":"1e3088",
"children":[
"Dumping syndrome results from rapid gastric emptying after gastric surgery; first-line treatment is smaller, more frequent meals with liquids taken following meals."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_gi_s2_10",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545-1575. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31278206",
"target":"_blank"
},
"children":[
"PMID: 31278206"
]
},
" doi:10.1136/gutjnl-2018-318126"
]
},
{
"type":"reference",
"children":[
"Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M19-1795",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;171:805-822. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31634917",
"target":"_blank"
},
"children":[
"PMID: 31634917"
]
}
]
},
{
"type":"reference",
"children":[
"Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112:212-239. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28071659",
"target":"_blank"
},
"children":[
"PMID: 28071659"
]
},
" doi:10.1038/ajg.2016.563"
]
},
{
"type":"reference",
"children":[
"Evans JA, Chandrasekhara V, Chathadi KV, et al; ASGE Standards of Practice Committee. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82:1-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25935705",
"target":"_blank"
},
"children":[
"PMID: 25935705"
]
},
" doi:10.1016/j.gie.2015.03.1967"
]
},
{
"type":"reference",
"children":[
"Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158:693-702. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31816298",
"target":"_blank"
},
"children":[
"PMID: 31816298"
]
},
" doi:10.1053/j.gastro.2019.12.003"
]
},
{
"type":"reference",
"children":[
"Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112:988-1013. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28631728",
"target":"_blank"
},
"children":[
"PMID: 28631728"
]
},
" doi:10.1038/ajg.2017.154"
]
},
{
"type":"reference",
"children":[
"Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27147122",
"target":"_blank"
},
"children":[
"PMID: 27147122"
]
},
" doi:10.1053/j.gastro.2016.02.011"
]
},
{
"type":"reference",
"children":[
"Syngal S, Brand RE, Church JM, et al; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-62; quiz 263. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25645574",
"target":"_blank"
},
"children":[
"PMID: 25645574"
]
},
" doi:10.1038/ajg.2014.435"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_gi_t05":{
"id":"mk19_a_gi_t05",
"number":5,
"bookId":"gi",
"title":{
"__html":"Structural and Other Causes of Dyspepsia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0c995f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 5. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t05"
}
]
},
"Structural and Other Causes of Dyspepsia"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3adbdb",
"class":"col hd l",
"children":[
"Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f8bc2",
"class":"col hd l",
"children":[
"Clinical Examples"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"301c19",
"class":"cell txt l",
"children":[
"Gastroesophageal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"532540",
"class":"cell txt l",
"children":[
"Gastroesophageal reflux disease, peptic ulcer disease, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" gastritis, gastric cancer/lymphoma, gastric amyloidosis, Ménétrier disease, gastroparesis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e29f4",
"class":"cell txt l",
"children":[
"Small bowel"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b3198f",
"class":"cell txt l",
"children":[
"Celiac disease, Crohn disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"342fbd",
"class":"cell txt l",
"children":[
"Pancreatic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"81840b",
"class":"cell txt l",
"children":[
"Pancreatitis, pancreatic cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"313760",
"class":"cell txt l",
"children":[
"Infectious"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d7e5",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Giardia lamblia"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Strongyloides stercoralis"
]
},
", tuberculosis, syphilis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d59a96",
"class":"cell txt l",
"children":[
"Common medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8cc74",
"class":"cell txt l",
"children":[
"NSAIDs, aspirin, iron, antibiotics (erythromycin, ampicillin), narcotics, estrogens and oral contraceptives, theophylline, levodopa, digitalis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"985763",
"class":"cell txt l",
"children":[
"Other systemic conditions"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0be00f",
"class":"cell txt l",
"children":[
"Coronary artery disease, kidney disease, thyroid dysfunction, adrenal insufficiency, hyperparathyroidism, pregnancy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_gi_t06":{
"id":"mk19_a_gi_t06",
"number":6,
"bookId":"gi",
"title":{
"__html":"Rome 4 Diagnostic Criteria for Functional Dyspepsia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"25c5d2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 6. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t06"
}
]
},
"Rome 4 Diagnostic Criteria for Functional Dyspepsia"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f3fff",
"class":"cell txt l",
"children":[
"One or more of the following",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
":"
]
},
" ",
{
"type":"p",
"hlId":"e5bcf5",
"class":"cell txt li",
"children":[
"Bothersome postprandial fullness"
]
},
" ",
{
"type":"p",
"hlId":"8cdb8c",
"class":"cell txt li",
"children":[
"Bothersome early satiation"
]
},
" ",
{
"type":"p",
"hlId":"1945a5",
"class":"cell txt li",
"children":[
"Bothersome epigastric pain"
]
},
" ",
{
"type":"p",
"hlId":"201596",
"class":"cell txt li",
"children":[
"Bothersome epigastric burning"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e44dad",
"class":"cell txt l",
"children":[
"No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis."
],
[
"Reproduced with permission from Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27147122",
"target":"_blank"
},
"children":[
"PMID: 27147122"
]
},
" doi:10.1053/j.gastro.2016.02.011. Copyright 2016, The AGA Institute."
]
]
},
"mk19_a_gi_t07":{
"id":"mk19_a_gi_t07",
"number":7,
"bookId":"gi",
"title":{
"__html":"Rome 4 Diagnostic Criteria for Postprandial Distress Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"678334",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t07"
}
]
},
"Rome 4 Diagnostic Criteria for Postprandial Distress Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3af90d",
"class":"col hd l",
"children":[
"Criteria",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f7f24",
"class":"col hd l",
"children":[
"Supportive Remarks"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6181d7",
"class":"cell txt l",
"children":[
"Must include one or both of the following at least 3 days per week:"
]
},
" ",
{
"type":"p",
"hlId":"2db968",
"class":"cell txt li",
"children":[
"Bothersome postprandial fullness (i.e., severe enough to affect usual activities)"
]
},
" ",
{
"type":"p",
"hlId":"bef134",
"class":"cell txt li",
"children":[
"Bothersome early satiation (i.e., severe enough to prevent finishing a regular-sized meal)"
]
},
" ",
{
"type":"p",
"hlId":"c5012d",
"class":"cell txt l",
"children":[
"No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including upper endoscopy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65f55e",
"class":"cell txt l",
"children":[
"Postprandial epigastric pain or burning, epigastric bloating, excessive belching, and nausea can also be present"
]
},
" ",
{
"type":"p",
"hlId":"62ffa7",
"class":"cell txt l",
"children":[
"Vomiting warrants consideration of another disorder"
]
},
" ",
{
"type":"p",
"hlId":"0faa53",
"class":"cell txt l",
"children":[
"Heartburn is not a dyspeptic symptom but may often coexist"
]
},
" ",
{
"type":"p",
"hlId":"84fa96",
"class":"cell txt l",
"children":[
"Symptoms that are relieved by evacuation of feces or gas should generally not be considered as part of dyspepsia"
]
},
" ",
{
"type":"p",
"hlId":"3dd145",
"class":"cell txt l",
"children":[
"Other individual digestive symptoms or groups of symptoms, such as from gastroesophageal reflux disease and irritable bowel syndrome, may coexist"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis."
],
[
"Reproduced with permission from Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27147122",
"target":"_blank"
},
"children":[
"PMID: 27147122"
]
},
" doi:10.1053/j.gastro.2016.02.011. Copyright 2016, The AGA Institute."
]
]
},
"mk19_a_gi_t08":{
"id":"mk19_a_gi_t08",
"number":8,
"bookId":"gi",
"title":{
"__html":"Rome 4 Diagnostic Criteria for Epigastric Pain Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"25455c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t08"
}
]
},
"Rome 4 Diagnostic Criteria for Epigastric Pain Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3af90d",
"class":"col hd l",
"children":[
"Criteria",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f7f24",
"class":"col hd l",
"children":[
"Supportive Remarks"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"557be1",
"class":"cell txt l",
"children":[
"Must include the following symptoms at least 1 day per week:"
]
},
" ",
{
"type":"p",
"hlId":"b5d248",
"class":"cell txt li",
"children":[
"Bothersome epigastric pain and/or burning (i.e., severe enough to affect usual activities)"
]
},
" ",
{
"type":"p",
"hlId":"c5012d",
"class":"cell txt l",
"children":[
"No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including upper endoscopy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83c823",
"class":"cell txt l",
"children":[
"Pain may be induced by ingestion of a meal, relieved by ingestion of a meal, or may occur while fasting"
]
},
" ",
{
"type":"p",
"hlId":"9f084f",
"class":"cell txt l",
"children":[
"Postprandial epigastric bloating, belching, and nausea can also be present"
]
},
" ",
{
"type":"p",
"hlId":"a7dc8f",
"class":"cell txt l",
"children":[
"Persistent vomiting suggests another disorder"
]
},
" ",
{
"type":"p",
"hlId":"0faa53",
"class":"cell txt l",
"children":[
"Heartburn is not a dyspeptic symptom but may often coexist"
]
},
" ",
{
"type":"p",
"hlId":"515cf7",
"class":"cell txt l",
"children":[
"The pain does not fulfill biliary pain criteria"
]
},
" ",
{
"type":"p",
"hlId":"84fa96",
"class":"cell txt l",
"children":[
"Symptoms that are relieved by evacuation of feces or gas should generally not be considered as part of dyspepsia"
]
},
" ",
{
"type":"p",
"hlId":"3dd145",
"class":"cell txt l",
"children":[
"Other individual digestive symptoms or groups of symptoms, such as from gastroesophageal reflux disease and irritable bowel syndrome, may coexist"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis."
],
[
"Reproduced with permission from Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27147122",
"target":"_blank"
},
"children":[
"PMID: 27147122"
]
},
" doi:10.1053/j.gastro.2016.02.011. Copyright 2016, The AGA Institute."
]
]
},
"mk19_a_gi_t09":{
"id":"mk19_a_gi_t09",
"number":9,
"bookId":"gi",
"title":{
"__html":"First-Line Treatment Options for <i>Helicobacter pylori</i> Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2261b9",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t09"
}
]
},
"First-Line Treatment Options for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9d1a1",
"class":"col hd l",
"children":[
"Treatment Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c85632",
"class":"col hd l",
"children":[
"Duration of Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"253824",
"class":"col hd l",
"children":[
"Clinical Indicators"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8eaf82",
"class":"cell txt l",
"children":[
"PPI, standard",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" or double dose twice daily (esomeprazole, once daily only)"
]
},
" ",
{
"type":"p",
"hlId":"45b7bd",
"class":"cell txt l",
"children":[
"Clarithromycin, 500 mg twice daily"
]
},
" ",
{
"type":"p",
"hlId":"bfe16a",
"class":"cell txt l",
"children":[
"Amoxicillin, 1 g twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e92d2",
"class":"cell txt l",
"children":[
"14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3eda1",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" clarithromycin resistance is known to be <15%"
]
},
" ",
{
"type":"p",
"hlId":"d590a6",
"class":"cell txt l",
"children":[
"No history of macrolide exposure for any reason"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"11a656",
"class":"cell txt l",
"children":[
"PPI, standard or double dose twice daily"
]
},
" ",
{
"type":"p",
"hlId":"45b7bd",
"class":"cell txt l",
"children":[
"Clarithromycin, 500 mg twice daily"
]
},
" ",
{
"type":"p",
"hlId":"30498c",
"class":"cell txt l",
"children":[
"Metronidazole, 500 mg three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e92d2",
"class":"cell txt l",
"children":[
"14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3eda1",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"H. pylori"
]
},
" clarithromycin resistance is known to be <15%"
]
},
" ",
{
"type":"p",
"hlId":"d590a6",
"class":"cell txt l",
"children":[
"No history of macrolide exposure for any reason"
]
},
" ",
{
"type":"p",
"hlId":"457e1b",
"class":"cell txt l",
"children":[
"Penicillin allergy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dda4e8",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily"
]
},
" ",
{
"type":"p",
"hlId":"b3dc92",
"class":"cell txt l",
"children":[
"Bismuth subcitrate, 120-300 mg or subsalicylate, 300 mg four times daily"
]
},
" ",
{
"type":"p",
"hlId":"9e177f",
"class":"cell txt l",
"children":[
"Tetracycline, 500 mg four times daily"
]
},
" ",
{
"type":"p",
"hlId":"abc8a2",
"class":"cell txt l",
"children":[
"Metronidazole, 250 mg four times daily or 500 mg three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8bbc1",
"class":"cell txt l",
"children":[
"10-14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"262816",
"class":"cell txt l",
"children":[
"Previous macrolide exposure"
]
},
" ",
{
"type":"p",
"hlId":"457e1b",
"class":"cell txt l",
"children":[
"Penicillin allergy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dda4e8",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily"
]
},
" ",
{
"type":"p",
"hlId":"45b7bd",
"class":"cell txt l",
"children":[
"Clarithromycin, 500 mg twice daily"
]
},
" ",
{
"type":"p",
"hlId":"bfe16a",
"class":"cell txt l",
"children":[
"Amoxicillin, 1 g twice daily"
]
},
" ",
{
"type":"p",
"hlId":"7b6ff8",
"class":"cell txt l",
"children":[
"Metronidazole or tinidazole, 500 mg twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8bbc1",
"class":"cell txt l",
"children":[
"10-14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b5d52",
"class":"cell txt l",
"children":[
"May be an alternative to standard clarithromycin triple therapy"
]
},
" ",
{
"type":"p",
"hlId":"e5d3e1",
"class":"cell txt l",
"children":[
"Not validated in North America"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dda4e8",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily"
]
},
" ",
{
"type":"p",
"hlId":"f60123",
"class":"cell txt l",
"children":[
"Levofloxacin, 500 mg once daily"
]
},
" ",
{
"type":"p",
"hlId":"bfe16a",
"class":"cell txt l",
"children":[
"Amoxicillin, 1 g twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8bbc1",
"class":"cell txt l",
"children":[
"10-14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b5d52",
"class":"cell txt l",
"children":[
"May be an alternative to standard clarithromycin triple therapy"
]
},
" ",
{
"type":"p",
"hlId":"e5d3e1",
"class":"cell txt l",
"children":[
"Not validated in North America"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PPI = proton pump inhibitor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Standard-dose PPIs: esomeprazole, 40 mg; lansoprazole, 30 mg; omeprazole, 20 mg; pantoprazole, 40 mg; rabeprazole, 20 mg."
],
[
"Adapted with permission from Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection. Am J Gastroenterol. 2017;112:212-239. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28071659",
"target":"_blank"
},
"children":[
"PMID: 28071659"
]
},
" doi:10.1038/ajg.2016.563."
]
]
},
"mk19_a_gi_t10":{
"id":"mk19_a_gi_t10",
"number":10,
"bookId":"gi",
"title":{
"__html":"Second-Line Treatment for <i>Helicobacter pylori</i> Infection After Failure of Initial Treatment"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"fe1f3d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t10"
}
]
},
"Second-Line Treatment for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" Infection After Failure of Initial Treatment"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9d1a1",
"class":"col hd l",
"children":[
"Treatment Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c85632",
"class":"col hd l",
"children":[
"Duration of Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"253824",
"class":"col hd l",
"children":[
"Clinical Indicators"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9351ca",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"14fdc2",
"class":"cell txt l",
"children":[
"Bismuth subcitrate, 120-300 mg, or subsalicylate, 300 mg four times daily"
]
},
" ",
{
"type":"p",
"hlId":"9e177f",
"class":"cell txt l",
"children":[
"Tetracycline, 500 mg four times daily"
]
},
" ",
{
"type":"p",
"hlId":"1e8f3c",
"class":"cell txt l",
"children":[
"Metronidazole, 500 mg three or four times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e92d2",
"class":"cell txt l",
"children":[
"14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e9c2d",
"class":"cell txt l",
"children":[
"Failure of clarithromycin-based or levofloxacin-based therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dda4e8",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily"
]
},
" ",
{
"type":"p",
"hlId":"f60123",
"class":"cell txt l",
"children":[
"Levofloxacin, 500 mg once daily"
]
},
" ",
{
"type":"p",
"hlId":"bfe16a",
"class":"cell txt l",
"children":[
"Amoxicillin, 1 g twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e92d2",
"class":"cell txt l",
"children":[
"14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06f3f9",
"class":"cell txt l",
"children":[
"Failure of bismuth-based or clarithromycin-based therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9351ca",
"class":"cell txt l",
"children":[
"PPI, standard dose twice daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"45b7bd",
"class":"cell txt l",
"children":[
"Clarithromycin, 500 mg twice daily"
]
},
" ",
{
"type":"p",
"hlId":"bfe16a",
"class":"cell txt l",
"children":[
"Amoxicillin, 1 g twice daily"
]
},
" ",
{
"type":"p",
"hlId":"3b2f95",
"class":"cell txt l",
"children":[
"Metronidazole or tinidazole, 500 mg twice or three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8bbc1",
"class":"cell txt l",
"children":[
"10-14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2853a5",
"class":"cell txt l",
"children":[
"Failure of bismuth-based therapy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PPI = proton pump inhibitor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Standard-dose PPIs: esomeprazole, 40 mg; lansoprazole, 30 mg; omeprazole, 20 mg; pantoprazole, 40 mg; rabeprazole, 20 mg."
],
[
"Adapted with permission from Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection. Am J Gastroenterol. 2017;112:212-239. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28071659",
"target":"_blank"
},
"children":[
"PMID: 28071659"
]
},
" doi:10.1038/ajg.2016.563."
]
]
},
"mk19_a_gi_t11":{
"id":"mk19_a_gi_t11",
"number":11,
"bookId":"gi",
"title":{
"__html":"Risk Factors for NSAID-Related Upper Gastrointestinal Complications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"cf1f59",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t11"
}
]
},
"Risk Factors for NSAID-Related Upper Gastrointestinal Complications"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8861c3",
"class":"cell txt l",
"children":[
"History of upper gastrointestinal bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee2b2a",
"class":"cell txt l",
"children":[
"History of peptic ulcer disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d23dbb",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"497cb4",
"class":"cell txt l",
"children":[
"Age >65 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"512d7e",
"class":"cell txt l",
"children":[
"Hemodialysis or peritoneal dialysis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c72d6",
"class":"cell txt l",
"children":[
"Use of high-dose or multiple NSAIDs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ed525",
"class":"cell txt l",
"children":[
"Concomitant use of aspirin (even low-dose), nonaspirin antiplatelet agents, anticoagulants, oral glucocorticoids, or selective serotonin reuptake inhibitors"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_gi_t12":{
"id":"mk19_a_gi_t12",
"number":12,
"bookId":"gi",
"title":{
"__html":"Causes of Gastroparesis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"747c10",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t12"
}
]
},
"Causes of Gastroparesis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6603b1",
"class":"col hd l",
"children":[
"Common Causes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"802ec1",
"class":"cell txt l",
"children":[
"Diabetes mellitus (40% in long-standing type 1 diabetes mellitus, 20% in type 2 diabetes mellitus)"
]
},
" ",
{
"type":"p",
"hlId":"3e1d60",
"class":"cell txt l",
"children":[
"Postsurgical (e.g., Nissen fundoplication, bariatric surgery, pancreatic surgery)"
]
},
" ",
{
"type":"p",
"hlId":"47eb1a",
"class":"cell txt l",
"children":[
"Idiopathic (e.g., postviral)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d82f1e",
"class":"col hd l",
"children":[
"Infrequent Causes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72a8f4",
"class":"cell txt l",
"children":[
"Connective tissue disease (e.g., systemic sclerosis)"
]
},
" ",
{
"type":"p",
"hlId":"c5b8c8",
"class":"cell txt l",
"children":[
"Neurologic disease (e.g., Parkinson disease)"
]
},
" ",
{
"type":"p",
"hlId":"9d0b19",
"class":"cell txt l",
"children":[
"Eating disorders"
]
},
" ",
{
"type":"p",
"hlId":"1eb03b",
"class":"cell txt l",
"children":[
"Hypothyroidism"
]
},
" ",
{
"type":"p",
"hlId":"97fa04",
"class":"cell txt l",
"children":[
"Amyloidosis"
]
},
" ",
{
"type":"p",
"hlId":"d91096",
"class":"cell txt l",
"children":[
"Paraneoplastic syndromes (e.g., small cell lung cancer)"
]
},
" ",
{
"type":"p",
"hlId":"6d6c83",
"class":"cell txt l",
"children":[
"Mesenteric ischemia"
]
},
" ",
{
"type":"p",
"hlId":"4563bc",
"class":"cell txt l",
"children":[
"Medications (e.g., opiates, anticholinergic agents)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_gi_t13":{
"id":"mk19_a_gi_t13",
"number":13,
"bookId":"gi",
"title":{
"__html":"Diagnostic Tests Assessing Gastric Emptying"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"5f5ef1",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 13. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gi_t13"
}
]
},
"Diagnostic Tests Assessing Gastric Emptying"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc66",
"class":"col hd l",
"children":[
"Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7b2ce",
"class":"col hd l",
"children":[
"Advantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd l",
"children":[
"Disadvantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7eb01",
"class":"col hd l",
"children":[
"Clinical Pearls"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a3c07",
"class":"cell txt l",
"children":[
"Gastric scintigraphy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8d96e",
"class":"cell txt l",
"children":[
"Considered the gold standard"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"761fb0",
"class":"cell txt l",
"children":[
"Radiation exposure (technetium radiolabeled meal)"
]
},
" ",
{
"type":"p",
"hlId":"8528f1",
"class":"cell txt l",
"children":[
"Requires specially trained personnel"
]
},
" ",
{
"type":"p",
"hlId":"20b4f7",
"class":"cell txt l",
"children":[
"Cost"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0717ba",
"class":"cell txt l",
"children":[
"Study lasting 4 hours is most accurate"
]
},
" ",
{
"type":"p",
"hlId":"17b549",
"class":"cell txt l",
"children":[
"Assesses solid emptying (liquid emptying is less accurate)"
]
},
" ",
{
"type":"p",
"hlId":"723649",
"class":"cell txt l",
"children":[
"Blood glucose should be <275 mg/dL (15.3 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b21e4",
"class":"cell txt l",
"children":[
"Wireless motility capsule"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06a42e",
"class":"cell txt l",
"children":[
"Can also assess small bowel, colon, and whole gut transit"
]
},
" ",
{
"type":"p",
"hlId":"f93fbf",
"class":"cell txt l",
"children":[
"No radiation"
]
},
" ",
{
"type":"p",
"hlId":"c2f770",
"class":"cell txt l",
"children":[
"Ambulatory study"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20b4f7",
"class":"cell txt l",
"children":[
"Cost"
]
},
" ",
{
"type":"p",
"hlId":"478ef9",
"class":"cell txt l",
"children":[
"Can't be used with pacemaker or implantable cardioverter-defibrillator"
]
},
" ",
{
"type":"p",
"hlId":"e9bdee",
"class":"cell txt l",
"children":[
"Risk for capsule retention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd5381",
"class":"cell txt l",
"children":[
"Consider in patient suspected of having global motility problem"
]
},
" ",
{
"type":"p",
"hlId":"666188",
"class":"cell txt l",
"children":[
"Stop antisecretory agents because study relies on measurement of pH"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ef7e7",
"class":"cell txt l",
"children":[
"Gastric emptying carbon breath test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f93fbf",
"class":"cell txt l",
"children":[
"No radiation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"774007",
"class":"cell txt l",
"children":[
"Avoid in setting of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Spirulina"
]
},
" supplementation or egg, milk, or wheat hypersensitivity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27e404",
"class":"cell txt l",
"children":[
"Accuracy adversely affected by conditions altering endogenous CO",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" production"
]
},
" ",
{
"type":"p",
"hlId":"ed3051",
"class":"cell txt l",
"children":[
"Avoid physical activity during testing"
]
},
" ",
{
"type":"p",
"hlId":"55f5bc",
"class":"cell txt l",
"children":[
"Avoid in patients with small-bowel malabsorption, pancreatic insufficiency, COPD, chronic heart failure, or advanced liver disease"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}